Program
AKT1 E17K Inhibitor ATV-1601
Also written as “ATV-1601” and “ATV-1601 + Fulvestrant”.
Its studies are mostly in Telangiectasia, Hereditary Hemorrhagic · Triple Negative Breast Neoplasms, led by Atavistik Bio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Atavistik Bio | 22 open or running | phase 2since May 12, 2026 | Jun 18, 2025 | Dec 2027phase 2 · NCT07601425 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 18, 2025First study: phase 1 study in Breast NeoplasmsFirst studyNCT07038369 · 134 enrolled · United States, France, Singapore and more
- May 12, 2026Phase 2 study in Telangiectasia, Hereditary HemorrhagicPhase 2 reachedNCT07601425 · 100 planned · United States, Argentina
Ahead
- Dec 2027Primary completion: phase 2 study in Telangiectasia, Hereditary HemorrhagicNCT07601425
- Aug 31, 2028Primary completion: phase 1 study in Breast NeoplasmsNCT07038369
TargetBeta
“An orally bioavailable non-covalent allosteric inhibitor of the serine/threonine protein kinase AKT (protein kinase B; v-akt murine thymoma viral oncogene homolog 1) isoform 1 mutation AKT1 E17K, ”NCIt, by rule
Other programs on AKT1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| capivasertibrule | AstraZeneca | phase 3 | 23 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07601425Telangiectasia, Hereditary Hemorrhagic · United States, Argentina | 2 | Recruiting | Dec 2027 | 100 |
| NCT07038369Breast Neoplasms · United States, France, Singapore and more | 1 | Active, not recruiting | Aug 31, 2028 | 134 |
How it is read
Names in the registry
- “ATV-1601”, 2 entries
- “ATV-1601 + Fulvestrant”, 1 entry
Conditions, from the studies’ own filings
- Telangiectasia, Hereditary Hemorrhagic, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.